Fifty People on Earth Have Brain Implants. Five Companies Just Expanded the List of Reasons to Get One by 10x.

Twenty-one days. Between April 18 and May 7, 2026, five separate companies implanted electrodes in human brains, published clinical results, or received FDA approval to start human trials, each targeting a different condition. BrainGate demonstrated a typing neuroprosthesis that hit 22 words per minute for two paralyzed patients, publishing in Nature Neuroscience. CorTec showed that its fully implanted wireless device could both stimulate a stroke patient's brain for rehabilitation and decode his thoughts into Pong gameplay, using the same hardware, without additional surgery. Motif Neurotech got the FDA's green light to begin the first clinical trial of a wireless depression implant small enough to sit inside a blueberry, a device that rests in a hole drilled through the skull but above the protective dura membrane, targeting a psychiatric condition without ever making direct contact with neural tissue. Illinois Institute of Technology implanted 544 electrodes in a third blind patient's visual cortex. And Synchron's endovascular BCI, threaded through the jugular vein with no craniotomy at all, completed 12 months of human safety monitoring without a single serious device-related adverse event.

None of these developments is, individually, the biggest story in neurotechnology this year. Together, they are.

The Convergence Nobody Counted

Here is what I have not seen anyone else quantify. Compile the patient populations across the five conditions these BCIs now target, using WHO and Global Burden of Disease estimates, and the numbers tell a story that no single press release captures.

Condition	BCI Platform	Global Patients (Millions)	Status
Spinal cord injury	BrainGate, Synchron, Neuralink	27.0	Active trials
ALS	BrainGate, Synchron	0.35	Active trials
Stroke (lasting disability)	CorTec Brain Interchange	101.0	Early feasibility
Treatment-resistant depression	Motif Neurotech	~100.0	FDA-approved trial starting
Blindness	ICVP	43.0	Third patient implanted
Total addressable pool		~271

Two years ago, the realistic BCI patient pool was essentially ALS plus severe spinal cord injury: roughly 27 million people worldwide, most of whom lived in countries without the neurosurgical infrastructure to implant anything. That pool has now expanded tenfold. Not because the technology suddenly became ten times better, but because five unrelated teams independently proved that the same fundamental capability, reading or writing electrical signals in brain tissue, could be redirected to problems that affect a hundred million people each.

Depression alone is staggering: the WHO estimates that 280 million people globally suffer from depressive disorders. Roughly 30 percent do not respond adequately to existing treatments, a population that dwarfs every other BCI indication combined. Motif Neurotech's DOT stimulator, a wireless device the size of a blueberry that sits in the skull above the dura without touching brain tissue, is not designed for the worried well. It targets people for whom multiple therapies have failed. Jacob Robinson, the Rice University professor who co-founded Motif, framed the ambition starkly in a press release: "The goal for this technology is that it would be the mental health equivalent of a continuous glucose monitor for diabetes."

Five Platforms, Five Approaches

What makes this convergence structurally interesting is that these are not five variations on the same design. Each team made fundamentally different engineering choices about how to get electrodes near neurons, and those choices determine which patients they can reach.

BrainGate used the most invasive approach of the five: microelectrode arrays, each carrying dozens of tiny silicon probes, implanted directly into the motor cortex through open cranial surgery, a procedure that demands specialized neurosurgical expertise and carries the inherent risks of any operation that breaches the skull and makes direct contact with brain tissue. The payoff is signal fidelity: their typing system mapped QWERTY keys to attempted finger movements, decoded the neural activity, and ran the output through a predictive language model. One participant, a person with advanced ALS, reached 22 words per minute at 1.6 percent word error rate, accuracy that matches able-bodied typing and obliterates the 3-to-5 words per minute typical of eye-gaze systems. Both participants used the device from home. Dr. Leigh Hochberg, who has led the BrainGate clinical trial since 2004, noted that the consortium has been working for over two decades to reach this point. That is not hyperbole: BrainGate filed its first IND in 2004.

CorTec took the opposite bet on invasiveness. Less depth, more longevity. Their Brain Interchange system uses AirRay electrodes placed on the brain surface, no penetration into tissue, which theoretically extends device longevity by reducing the scar tissue that eventually degrades signal quality in penetrating arrays. The remarkable result is not the Pong gameplay itself; it is that the same fully implanted, wireless device that was delivering therapeutic cortical stimulation for stroke rehabilitation also decoded the patient's motor intentions for computer control without any modification. "No strategic pivot and not a new product," CEO Dr. Frank Desiere said. "It is empirical proof of what we have been building for more than a decade." The patient had been implanted for nine months. Within two hours of being told he could try to control a computer with his thoughts, he was playing Pong. The device had already logged 500 continuous days of stable operation in a previous dataset published in Nature Scientific Data.

Synchron avoided brain surgery entirely. Their Stentrode, a self-expanding stent-electrode array, is delivered through the jugular vein and lodges in a blood vessel adjacent to the motor cortex. The SWITCH trial, led by Bruce Campbell, monitored patients for 12 months and reported zero serious device-related adverse events, a result that matters enormously for regulatory strategy because the biggest barrier to widespread BCI adoption is not signal quality but the willingness of patients and insurers to accept the risk of brain surgery. An endovascular procedure that carries roughly the same risk profile as a cardiac stent insertion changes the adoption math for the entire field, because the population of patients willing to accept a catheter threaded through a vein is dramatically larger than the population willing to accept open cranial surgery, and it is patient willingness to accept surgical risk, not signal quality, that currently constrains how fast BCIs can scale. Synchron also became the first company to integrate its BCI with Apple devices through the new BCI Human Interface Device protocol, enabling ALS patients to control iPhones and iPads via thought.

Motif Neurotech sits somewhere between non-invasive and fully implanted. Their DOT stimulator is placed in a hole drilled in the skull but rests above the dura, the protective membrane that covers the brain, meaning it never contacts neural tissue. It delivers targeted electrical stimulation to circuits associated with depression. The FDA approved their first clinical trial in collaboration with seven institutions including Baylor College of Medicine, Mass General Brigham, and Emory Healthcare. ARPA-H also selected Motif for the EVIDENT initiative, a $139.4 million program aimed at accelerating behavioral health interventions, and the company closed an oversubscribed $18.75 million Series A last year, capital raised during a period when most neurotech startups were struggling to close even bridge rounds.

ICVP represents the most ambitious target: replacing an entire sensory modality. The Intracortical Visual Prosthesis, developed at Illinois Institute of Technology, implants dozens of miniaturized wireless stimulators directly into the visual cortex, bypassing damaged eyes and optic nerves entirely. The third patient received 34 individual stimulators carrying a combined total of 544 electrodes, all implanted during a single surgical session at Rush University Medical Center, representing one of the densest cortical electrode implantations ever performed for the purpose of artificially restoring a sensory modality. After four weeks of recovery, researchers will test whether the patient can interpret the artificial signals well enough to navigate environments. "Even the ability to perceive a small amount of light can profoundly impact daily lives," said Janet P. Szlyk, President and CEO of The Chicago Lighthouse, where participants train with the device.

The Trojan Horse Math

There is a pattern buried in these five announcements that becomes visible only when you stack them chronologically and ask: who gets the implant first, and why?

Every platform started with the most severe cases. BrainGate's participants have ALS or complete spinal cord injuries. Synchron's SWITCH trial enrolled people with upper-limb paralysis. CorTec's first patient had a stroke. These are populations with few alternatives and enormous motivation to accept surgical risk. Regulators approve trials for them because the risk-benefit calculation is unambiguous: a person who cannot move or communicate has little to lose from an experimental implant.

But once the device is in the skull and the safety data accumulates across dozens and then hundreds of patient-years of continuous monitoring, the clinical indications expand outward into progressively larger patient populations, each new indication justified by the evidence gathered from the last. CorTec's four-pillar clinical strategy is explicit about this: stroke rehabilitation first, then epilepsy at Mayo Clinic, then BCI for paralysis, then treatment-resistant depression at University Hospital Freiburg. Same platform, same hardware, four conditions with progressively larger patient populations. Motif skipped the paralysis step entirely and went straight to depression, which affects orders of magnitude more people than motor impairment.

Run the numbers forward. If even 1 percent of treatment-resistant depression patients eventually become candidates for a Motif-style implant, that is one million people, twenty times the current number of cochlear implant recipients in the United States. If 0.1 percent of stroke survivors with lasting disability receive a CorTec-style device, that is 100,000 implants per year globally. These are conservative figures applied to populations that already exist, not projections based on a technology that has yet to prove itself.

What the BCI Market Actually Looks Like

Precedence Research values the global BCI market at $2.94 billion in 2025 and projects it to reach $13.86 billion by 2035, a 16.77 percent compound annual growth rate. That forecast was published before three of the five milestones described in this article occurred. The model almost certainly underestimates the depression and blindness segments because those indications were not in active human trials when the projections were made.

Investment patterns tell a parallel story: Neuralink raised $205 million, Synchron has raised over $145 million, and Motif closed $18.75 million for a device that fits in your thumbnail. CorTec's funding is smaller but its FDA Breakthrough Device Designation, one of only a handful granted specifically for therapeutic BCI, gives it a regulatory fast lane that money alone cannot buy.

Limitations

Roughly fifty people on Earth currently have implanted BCIs of any kind. Fifty. The gap between "five platforms crossed clinical milestones" and "BCIs are a routine medical device" is measured in decades, not years. No BCI has received full FDA approval for commercial sale. No insurer covers them. No published trial has enrolled more than a few dozen participants. The 271-million-patient figure in the table above represents theoretical addressability, not demonstrated demand, and the history of medical devices is full of technologies that were theoretically perfect for millions of people and practically adopted by thousands.

Delivery timelines are uncertain across every platform. BrainGate's 22-wpm typing result comes from two patients. CorTec's dual-function demonstration is from a single patient. Motif has not yet implanted anyone, and ICVP has implanted only three. These are feasibility studies, not Phase III trials, and the regulatory path from "early feasibility" to "PMA approval" typically takes five to ten years at minimum for implantable neural devices.

Signal longevity remains an unsolved problem for penetrating arrays. Scar tissue forms around electrodes over months to years, degrading the signal-to-noise ratio and eventually rendering some channels unusable. CorTec's surface electrodes and Synchron's endovascular approach were both designed to mitigate this, but neither has published data beyond five years. Whether these devices function reliably at the ten-year mark, the minimum useful lifespan for a chronic implant, is unknown.

Strongest Counterargument

The strongest case against the convergence narrative is that simultaneous milestones do not imply coordinated progress toward a shared endpoint. These five platforms serve different conditions, use incompatible hardware, face different regulatory pathways, and will be evaluated by different medical specialties. A typing neuroprosthesis for ALS and a depression stimulator share approximately as much technology as a pacemaker and a hearing aid: both are implantable, both use electrodes, and the comparison ends there. Lumping them into a single "BCI convergence" story risks creating the impression of a unified field marching toward a common future, when the reality is five separate bets with five separate failure modes. CorTec's brain-surface electrodes may not capture enough signal bandwidth for high-speed communication. Motif's depression stimulator may not outperform transcranial magnetic stimulation, which does not require any surgery at all. ICVP's 544 electrodes may produce visual percepts too crude for practical navigation. Treating these as evidence of a single trend is a framing choice, not an empirical conclusion, and the framing flatters the field more than the data warrants.

What You Can Do

If you have ALS, a spinal cord injury, or a stroke with lasting motor impairment, multiple BCI clinical trials are actively recruiting. ClinicalTrials.gov lists open studies searchable by condition and location. Search for "brain-computer interface" plus your condition. BrainGate recruits through Mass General Brigham. Synchron's SWITCH trial sites span multiple countries. CorTec's early feasibility study is at the University of Washington.

If you have treatment-resistant depression and have tried multiple medications without adequate relief, Motif Neurotech is recruiting eligible adults for their first clinical trial, conducted across eight institutions including Baylor College of Medicine, Mass General Brigham, and Emory Healthcare. The device does not require open brain surgery, which distinguishes it from most other BCI trials.

If you lost vision in adulthood after at least a decade of normal sight, the ICVP study at Illinois Institute of Technology is recruiting additional volunteers. Contact the Pritzker Institute of Biomedical Science and Engineering for enrollment details.

If you are an investor or analyst modeling the BCI sector, update your total addressable market calculations. The standard approach, sizing the market around ALS and spinal cord injury, no longer reflects the clinical pipeline. Depression alone represents a patient population that exceeds all other current BCI indications combined by an order of magnitude, and the Motif trial is the first step toward quantifying whether the technology works for that population.

The Bottom Line

Five platforms. Five conditions. Three weeks. Approximately fifty humans on Earth currently live with a brain-computer interface of any kind, a population so small that they could all fit in a single lecture hall. The clinical pipeline now targets a combined patient pool of 271 million people globally. The gap between those two numbers is the entire story of where this field is going. Whether these devices actually reach significant numbers of patients depends on trials that will take years, regulatory processes that will take longer, and insurance coverage decisions that have not even begun. But the engineering question, can you safely put electrodes in a human brain and read or write useful signals, has been answered five different ways in three weeks. What remains is the implementation, and the market just got ten times larger than anyone was modeling.

Related

• Five Companies Are Racing to Wire the Human Brain. Here's Who's Winning.
• Neuralink Has 1,024 Electrodes and 21 Patients. Synchron Has 16 Electrodes and a Peer-Reviewed Safety Record.
• He Got a Brain Implant for Stroke Rehab. Two Hours Later He Was Playing Pong with It.